Equities Analysts Set Expectations for HALO Q1 Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Halozyme Therapeutics in a report released on Sunday, January 12th. Leerink Partnrs analyst D. Risinger forecasts that the biopharmaceutical company will post earnings per share of $0.93 for the quarter. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.80 per share. Leerink Partnrs also issued estimates for Halozyme Therapeutics’ Q2 2025 earnings at $1.04 EPS, Q3 2025 earnings at $1.41 EPS and FY2029 earnings at $8.16 EPS.

A number of other equities analysts also recently commented on HALO. JMP Securities raised their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. HC Wainwright raised their target price on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Piper Sandler raised their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. Wells Fargo & Company cut their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday. Finally, JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $60.89.

Halozyme Therapeutics Stock Up 1.3 %

Shares of HALO opened at $54.51 on Tuesday. The company’s fifty day moving average is $49.83 and its two-hundred day moving average is $54.06. Halozyme Therapeutics has a fifty-two week low of $33.15 and a fifty-two week high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The firm has a market cap of $6.94 billion, a PE ratio of 18.05, a price-to-earnings-growth ratio of 0.44 and a beta of 1.24.

Insider Buying and Selling

In other news, Director Jeffrey William Henderson sold 10,000 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the sale, the director now owns 43,611 shares in the company, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of institutional investors have recently modified their holdings of HALO. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Halozyme Therapeutics in the 2nd quarter valued at about $49,000. GAMMA Investing LLC raised its stake in shares of Halozyme Therapeutics by 67.7% in the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 350 shares in the last quarter. Toth Financial Advisory Corp acquired a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at about $57,000. FSC Wealth Advisors LLC bought a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at about $65,000. Finally, Park Place Capital Corp grew its position in shares of Halozyme Therapeutics by 828.1% during the 3rd quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company’s stock valued at $78,000 after buying an additional 1,209 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.